Xintela ABOSTO:XINT +1.49%8 FCF Yield % is -25.27 as of Jul. 04, 2026. GuruFocus rates OSTO:XINT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Xintela AB ranks worse than 72.19% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Xintela AB FCF Yield % Related Terms
Xintela AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Xintela AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:XINT vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Xintela AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xintela AB FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xintela AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Xintela AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB (OSTO:XINT) has a FCF Yield % of -25.27 as of Jul. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #1020 out of 1413 companies in the Biotechnology industry, placing it in the top 72.2%.
Is Xintela AB's FCF Yield % too high?
Xintela AB's current FCF Yield % is -25.27. Based on the distribution chart, Xintela AB ranks #1020 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #1020 out of 1413 companies for FCF Yield %. This places Xintela AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Xintela AB and its competitors. Xintela AB's current FCF Yield % is -25.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (OSTO:XINT) has a current FCF Yield % of -25.27. The current FCF Yield % is -25.27. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Xintela AB (OSTO:XINT), the current FCF Yield % is -25.27 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score
Get the complete analysis for OSTO:XINT
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:XINT has been successfully added to your 
